Does 17-α-hydroxyprogesterone caproate affect fetal biometry and birth weight in twin pregnancy?

Ultrasound in Obstetrics and Gynecology

Volumn 42, Issue 3, 2013, Pages 329-334

  Mulder, E J H ^a   Versteegh, E M J ^b   Bloemenkamp, K W M ^b   Lim, A C ^c   Mol, B W J ^c   Bekedam, D J ^d   Kwee, A ^a   Bruinse, H W ^a   Christiaens, G C M L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

Author keywords

17 hydroxyprogesterone caproate; fetal growth; preterm birth; twins

Indexed keywords

17-ALPHA-HYDROXY-PROGESTERONE CAPROATE; GESTAGEN; PROGESTERONE DERIVATIVE; HYDROXYPROGESTERONE CAPROATE;

ADULT; BIOMETRY; BIRTH WEIGHT; BODY SIZE; DRUG EFFECTS; FEMALE; GESTATIONAL AGE; HUMAN; MALE; NEWBORN; OBSTETRIC LABOR, PREMATURE; PREGNANCY; RISK FACTOR; SECOND TRIMESTER PREGNANCY; SEX DIFFERENCE; THIRD TRIMESTER PREGNANCY; TREATMENT OUTCOME; TWIN PREGNANCY; TWINS; 17-Α-HYDROXYPROGESTERONE CAPROATE; ARTICLE; DRUG EFFECT; FETUS GROWTH; PREMATURE LABOR;

ADULT; BIOMETRY; BIRTH WEIGHT; BODY SIZE; FEMALE; GESTATIONAL AGE; HUMANS; HYDROXYPROGESTERONES; INFANT, NEWBORN; MALE; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; PREGNANCY, TWIN; PROGESTINS; RISK FACTORS; SEX FACTORS; TREATMENT OUTCOME; TWINS;

17-Α-HYDROXYPROGESTERONE CAPROATE; FETAL GROWTH; PRETERM BIRTH; TWINS;

EID: 84883556601     PISSN: 09607692     EISSN: 14690705     Source Type: Journal    
DOI: 10.1002/uog.12486     Document Type: Article

References (22)

1. th revision). World Health Organization: Geneva, 1992.
2. Meis PJ, Klebanoff M, Thom E, Dombrovski MP, Sibai B, Moawad AH, Spong CY, Hauth JC, Miodovnik M, Varner MW, Leveno KJ, Caritis SN, Iams JD, Wapner RJ, Conway D, O'Sullivan MJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S,; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17-alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348: 2379-2385.
3. Da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M,. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double blind study. Am J Obstet Gynecol 2003; 188: 419-424.
4. Likis FE, Velez Edwards DR, Andrews JC, Woodworth AL, Jerome RN, Fonnesbeck CJ, McKoy JN, Hartmann KE,. Progestogens for preterm birth prevention: a systematic review and meta-analysis. Obstet Gynecol 2012; 120: 897-907.
5. Zakar T, Mesiano S,. How does progesterone relax the uterus in pregnancy? N Engl J Med 2011; 364: 972-973.
6. O'Brien JM,. The safety of progesterone and 17-hydroxyprogesterone caproate administration for the prevention of preterm birth: an evidence-based assessment. Am J Perinatol 2012; 29: 665-672.
7. Behrman RE, Butler AS (eds). Preterm birth: Causes, Consequences, and Prevention. The National Academies Press: Washington, DC, 2006.
8. Christian MS, Brent RL, Calda P,. Embryo-fetal toxicity signals for 17alpha-hydroxyprogesterone caproate in high-risk pregnancies: a review of the non-clinical literature for embryo-fetal toxicity with progestins. J Matern Fetal Neonatal Med 2007; 20: 89-112.
9. Calda P., Safety signals of 17-OHP-C use in pregnancy and efficacy in prevention of preterm birth. J Matern Fetal Neonatal Med 2009; 22: 540-542.
10. Lim AC, Schuit E, Bloemenkamp K, Bernardus RE, Duvekot JJ, Erwich JJHM, van Eyck J, Groenewold RHH, Hasaart THM, Hummel P, Kars MM, Kwee A, van Oirschot CM, van Pampus MG, Papatsonis D, Porath MM, Spaanderman ME, Willekes C, Wilpshaar J, Mol BWJ, Bruinse HW,. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies. Obstet Gynecol 2011; 118: 513-520.
11. Verburg BO, Steegers EAP, de Ridder M, Snijders RJM, Smith E, Hofman A, Moll HA, Jaddoe VW, Witteman JC,. New charts for ultrasound dating of pregnancy and assessment of fetal growth: longitudinal data from a population-based cohort study. Ultrasound Obstet Gynecol 2008; 31: 388-396.
12. Romero R, Nicolaides K, Conde-Agudelo A, Tabor A, O'Brien JM, Cetingoz E, Da Fonseca E, Creasy GW, Klein K, Rode L, Soma-Pillay P, Fusey S, Cam C, Alfirevic Z, Hassan SS,. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol 2012; 206: 124.e1-19.
13. Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M, Vijayaraghavan J, Trivedi Y, Soma-Pillay P, Sambarey P, Dayal A, Potapov V, O'Brien J, Astakhov V, Yuzko O, Kinzler W, Dattel B, Sehdev H, Mazheika L, Manchulenko D, Gervasi MT, Sullivan L, Conde-Agudelo A, Phillips JA, Creasy GW,. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2011; 38: 18-31.
14. Norman JE, Mackenzie F, Owen P, Mactier H, Hanretty K, Cooper S, Calder A, Mires G, Danielian P, Sturgiss S, MacLennan G, Tydeman G, Thornton S, Martin B, Thornton JG, Neilson JP, Norrie J,. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebo-controlled study and meta-analysis. Lancet 2009; 373: 2034-2040.
15. Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY, Varner M, Malone F, Iams JD, Mercer BM, Thorp J, Sorokin Y, Carpenter M, Lo J, Ramin S, Harper M, Anderson G,; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 2007; 357: 454-461.
16. Rode L, Klein K, Nicolaides KH, Krampl-Bettelheim E, Tabor A,; PREDICT Group. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone. Ultrasound Obstet Gynecol 2011; 38: 272-280.
17. Northen AT, Norman GS, Anderson K, Moseley L, Divito M, Cotroneo M, Swain M, Bousleiman S, Johnson F, Dorman K, Milluzzi C, Tillinghast JA, Kerr M, Mallett G, Thom E, Pagliaro S, Anderson GD,; National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo. Obstet Gynecol 2007; 110: 865-872.
18. Sibai BM, Istwan NB, Palmer B, Stanziano GJ,. Pregnancy outcome of women receiving compounded 17α-hydroxyprogesterone caproate for prophylactic prevention of preterm birth 2004 to 2011. Am J Perinatol 2012; 29: 635-642.
19. Carbone JP, Brent RL,. Genital and nongenital teratogenesis of prenatal progestogen therapy: the effects of 17 alpha-hydroxyprogesterone caproate on embryonic and fetal development and endochondral ossification in the C57B1/6 J mouse. Am J Obstet Gynecol 1993; 169: 1292-1298.
20. Gielen M, Lindsey PJ, Derom C, Loos RJF, Derom R, Nijhuis JG, Vlietinck R,. Twin birth weight standards. Neonatology 2007; 92: 164-173.
21. Hack K, Derks J, Elias S, Franx A, Roos EJ, Voerman SK, Bode CL, Koopman-Esseboom C, Visser GH,. Increased perinatal mortality and morbidity in monochorionic versus dichorionic twin pregnancies: clinical implications of a large Dutch cohort study. BJOG 2008; 115: 58-67.
22. Helmerhorst FM, Perquin DA, Donker D, Keirse MJ,. Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies. BMJ 2004; 328: 261.